Q4 2026 AngioDynamics Inc Earnings Call Transcript
Key Points
- AngioDynamics Inc (ANGO) reported a strong fourth quarter, with an 8% increase in revenue to $86.6 million, driven by growth across both MedTech and Med Device segments.
- The MedTech segment saw a significant 16.7% increase in revenue, with platforms like Auryon delivering double-digit year-over-year growth for 20 consecutive quarters.
- NanoKnife revenue increased by 64.5%, driven by record procedure volumes and strong demand in prostate care.
- The company maintained a strong, debt-free balance sheet with $53.9 million in cash, allowing for continued investment in growth initiatives.
- AngioDynamics Inc (ANGO) is positioned in large, fast-growing markets, with a strategy focused on innovation and clinical data to drive adoption and expand market share.
- Despite revenue growth, AngioDynamics Inc (ANGO) reported a net loss of $11.4 million for the fourth quarter, with an adjusted net loss of $2.8 million.
- Mechanical Thrombectomy revenue decreased by 1.1% year-over-year, with AngioVac sales declining by 15.8%, indicating challenges in this competitive market.
- The company faced tariff expenses of approximately $4.8 million for the full year, impacting overall profitability.
- Operating expenses increased to $57 million in the fourth quarter, representing 66% of sales, up from 60% in the previous year.
- The adjusted EBITDA for the fourth quarter was slightly down at $3.3 million compared to $3.4 million in the same quarter of the previous year.
Good morning, and welcome to the AngioDynamics fiscal year 2026 fourth-quarter and full-year earnings call. (Event Instructions)
The news release detailing AngioDynamics fiscal 2026 fourth-quarter and full-year results crossed the wire earlier this morning and is available on the company's website. This conference call is also being broadcast live over the internet at the Investors section of the company website at www.angiodynamics.com. A webcast replay of the call will be available at the same site approximately one hour after the end of today's call.
Before we begin, I'd like to caution listeners that during the course of this conference call, the company will make projections or forward-looking statements regarding future events, including statements about expected revenue, adjusted earnings, and gross margin for fiscal year 2027, as well as trends that may continue.
Management encourages you to review the company's past and future filings with the SEC, including, without limitation, the company's Forms
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
